![We Care for Every Heartbeat]({"type":"image" , "src" : "/sda/112416/JournalAd-TACD-Daiichi.jpg"})
References
- Ceriello A, dello Russo P, Amstad P, et al. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes. 1996;45:471–477.
- Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes. 1985;34:621–627.
- Asahina T, Kashiwagi A, Nishio Y, et al. Impaired activation of glucose oxidation and nadph supply in human endothelial cells exposed to h2o2 in high-glucose medium. Diabetes. 1995;44:520–526.
- Kim JA, Berliner JA, Natarajan RD, et al. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes. 1994;43:1103–1107.
- Fontbonne A, Eschwege E. Diabetes, hyperglycaemia, hyperinsulinaemia and atherosclerosis: epidemiological data. Diabete Metab. 1987;13:350–353.
- Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances icam-1, vcam-1 and e-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase c and mitochondrial superoxide production. Atherosclerosis. 2005;183:259–267.
- Fabbri G, Maggioni AP. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Adv Ther. 2009;26:469–487.
- Kim YS, Ahn Y, Hong MH, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor-kappaB in endothelial cells. J Cardiovasc Pharmacol. 2007;49:376–383.
- Kim SW, Kim CE, Kim MH. Flavonoids inhibit high glucose-induced up-regulation of ICAM-1 via the p38 MAPK pathway in human vein endothelial cells. Biochem Biophys Res Commun. 2011;415:602–607.
- Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.
- Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–126.
- Kado S, Wakatsuki T, Yamamoto M, et al. Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. Life Sci. 2001;68:727–737.
- Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation. 1997;96:4219–4225.
- Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255–1262.
- Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: a collaborative approach. Circulation. 2005;112:3184–3209.
- McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28–B-32.
- Fadini GP, Albiero M, Boscaro E, et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int. 2010;34:709–715.
- Monetti M, Canavesi M, Camera M, et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoe-deficient mice. Pharmacol Res. 2007;55:441–449.
- Schroeter MR, Humboldt T, Schafer K, et al. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein knockout mice. Atherosclerosis. 2009;205:63–73.
- Li W, Asagami T, Matsushita H, et al. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J Pharmacol Exp Ther. 2005;313:557–562.
- Cameron N, Cotter M, Inkster M, et al. Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract. 2003;61(Suppl 1):S35–S39.
- Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92:689–737.
- Gan J, Li P, Wang Z, et al. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Exp Ther Med. 2013;6:899–903.
- Luo B, Li B, Wang W, et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther. 2014;28:33–43.
- Tian XY, Wong WT, Xu A, et al. Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. Br J Pharmacol. 2011;164:598–606.
- Wang M, Li Z, Zhang X, et al. Rosuvastatin attenuates atrial structural remodelling in rats with myocardial infarction through the inhibition of the p38 MAPK signalling pathway. Heart Lung Circ. 2015;24:386–394.
![Novo Nordisk – Driving change to defeat serious chronic diseases.]({"type":"image" , "src" : "/sda/112384/TACD_NovoNordisk.jpg"})
![Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.]({"type":"image" , "src" : "/sda/112392/Skyscraper_BristolMyersSquibb.jpg"})